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ABSTRACT
The peripheral T cell lymphomas (PTCL) carry a worse prognosis compared to B cell non-Hodgkin lym-
phoma. There is no uniform standard therapy for PTCL, and autologous hematopoietic cell transplant
(AHCT) is often offered as consolidation in first remission or at relapse because of the poor outcomes with
conventional therapy. We conducted a retrospective review of patients who underwent AHCT for PTCL
from 1989 to 2006. Fifty-three cases were identified consisting of systemic anaplastic large cell (n 5 18),
PTCL unspecified (n 5 17), angioimmunoblastic (n 5 9), nasal type extranodal NK/T (n 5 7), hepatosplenic
(n5 2), and adult T cell leukemia/lymphoma (n5 1). Fifteen patients were transplanted in first complete or par-
tial response (CR1/PR1), 32 in second or beyond CR or PR (CR2/PR21), and 11 with primary refractory disease
(REF). With a median follow-up was 5 years (range: 1.0-11.5), the 5-year progression-free survival (PFS) and
overall survival (OS) were 25% and 48%, respectively. Disease status at AHCT had a significant impact on
PFS and OS. The 5-year PFS for patients in CR1/PR1, CR2/PR21, and REF was 51%, 12%, and 0%, respec-
tively, and the corresponding figures for OS were 76%, 40%, and 30%, respectively. The pretransplant factors
that impacted survival were disease status and the number of prior regimens. Histology, age, sex, stage, B
symptoms, bonemarrow involvement, and duration of first response did not significantly affect PFS orOS. Based
on these results, AHCT as consolidation therapy in first complete or partial responsemay offer a durable survival
benefit. However, AHCT with conventional salvage chemotherapy has minimal durable benefit in patients with
relapsed or refractory PTCL, and thus novel strategies and/or allogeneic HCT should be more aggressively
explored in lieu of AHCT for relapsed/ refractory PTCL.
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The peripheral T cell lymphomas (PTCL) are
a rare and heterogeneous group of disorders. PTCL
accounts for approximately 10% of all lymphomas,
and the most common types of PTCL are PTCL
unspecified (PTCL-U), systemic anaplastic large cell
lymphoma (ALCL), and angioimmunoblastic T cell
lymphoma (AITL), although nasal type extranodal
NK/T cell lymphoma (nNK/T) is more frequent in
East Asia. Excluding anaplastic lymphoma kinase
expressing (ALK1) ALCL, PTCL has a poor progno-
sis, with a 5-year disease free survival (DFS) of\30%
[1]. Compared to the aggressive B cell lymphomas, theprognosis of patients with PTCL is considerably
inferior.
To improve on this poor outcome, autologous
hematopoietic cell transplantation (AHCT) has been
offered to patients with PTCL as consolidation in first
remission and for relapsed or refractory disease (REF).
However, most studies have been limited in sample
size and duration. Variable response rates have been
reported, which probably reflect interstudy differences
in disease status, risk factors, types of PTCL, and
duration of follow-up. Recent retrospective studies in
the relapsed and refractory setting have reported an
estimated DFS or progression-free survival (PFS)741
742 A. I. Chen et al.ranging from 18%-34% at 5 years following AHCT
[2-4]. As an upfront consolidation strategy, results
from prospective studies have been contradictory
regarding benefit [5,6]. We conducted a retrospective
review and report our single center experience of
patients who underwent AHCT for PTCL at Stanford
University.
METHODS
Study Population
Patients who underwent AHCT from1988 to 2006
for PTCLwere identified from the StanfordUniversity
Blood and Marrow Transplantation database. Patients
with lymphoblastic lymphoma, primary leukemias, and
primary cutaneous disease were excluded. Response
criteria were defined according to the International
Harmonization Project guidelines with the addition
of REF, which was defined as a response less than
partial remission (PR) to induction therapy as multiple
induction regimens were allowed [7]. All patients had
an Eastern Cooperative Oncology Group (ECOG)
performance status of\2 and had adequate cardiac,
hepatic, and renal function prior to transplant. Interna-
tional prognostic index (IPI) and prognostic index for
PTCL-U (PIT) were not included in this analysis
because ofmissing data for lactate dehydrogenase at di-
agnosis and at the time of transplant on most patients.
All pathology was reviewed by the Stanford Pathology
Department to confirm diagnosis.
Transplant Procedures
Patients underwent hematopoietic cell collection
either by bone marrow harvest or leukapheresis
following cyclophosphamide (4 gm/m2) and filgastrim
(10 mg/kg) mobilization. Grafts were T cell purged
either by negative selection with monoclonal antibody
(mAb) and complement [8] or by CD341-positive se-
lection using the Isolex immunomagnetic column
[9]. Assessment of residual tumor in the purged grafts
was not performed. The high-dose chemotherapy
regimen consisted of carmustine, etoposide, and cyclo-
phosphamide as previously described [10]. The total
body irradiation (TBI)-based regimen consisted of
TBI, etoposide, and cyclophosphamide. Formal re-
sponse assessments with radiologic imaging and bone
marrow biopsies were performed at 3, 6, and 12
months post-HCT and annually thereafter, unless an
earlier time point was clinically indicated.
Statistics
Overall survival (OS) and PFS were estimated
according to the Kaplan-Meier method. The variables
of interest were disease status at AHCT, number of
prior regimens, histologic subtype, sex, age, advanced
stage, B symptoms, bone marrow involvement, dura-
tion of CR1 for patients with relapsed disease, andCR status at day 1 90 post-AHCT. Variables of
interest were compared using the log-rank test. Multi-
variate analysis was performed using the Cox propor-
tional hazards model. Multivariate and day 190
posttransplant statistics utilized a landmark analysis
at day 190. Statistics were calculated using the R
program (R Foundation for Statistical Computing,
version 2.6.2, 2008, Vienna, Austria).
RESULTS
Patient Characteristics
Patient characteristics are listed in Table 1. The
median age at AHCT was 45 years (range: 18-73),
and 57%were male. Fifteen patients were transplanted
in first complete or partial response (CR1/PR1), 26 in
second complete or partial response or beyond (CR2/
PR21), and 10 with primary REF. Twelve of 15 pa-
tients transplanted in first response were in CR with
3 patients in PR. Six of 15 patients transplanted in
CR1/PR1 required 2 or more regimens to achieve first
response. Of the 2 patients with ALCL transplanted in
first response, 1 had ALK- ALCL, and the other with
ALK1 ALCL required 3 different induction regimens
to reach PR1. Of the 26 patients transplanted in CR2/
PR21, 16 were in CR. The autologous graft source
was mobilized peripheral blood in 86% and bone
Table 1. Patient Characteristics
Disease Status
at AHCT CR1/PR1 CR2/PR21 REF
Number of cases 15 28 10
Age (range) 49 (18-63) 46 (24-67) 38 (25-73)
Sex (M/F) 5/10 19/9 5/5
Histology
Unspecified 2 10 4
ALCL 2 13 3
AITL 4 4 1
nNK/T 5 0 2
Other* 2 1 0
Number prior
regimens (range)
1 (1-4) 2 (1-5) 3 (1-3)
Stage at initial diagnosis
I-II 3 9 1
III-IV 12 19 9
B symptoms 10 11 3
Marrow involvement 8 5 6
Median months from
diagnosis to AHCT (range)
7 (3-17) 20 (9-192) 11 (4-17)
Conditioning regimen
Chemotherapy only 13 24 7
TBI based 2 4 3
T cell depletion 13 22 9
AHCT indicates autologous hematopoietic cell transplant; ALCL,
anaplastic large cell lymphoma; AITL, angioimmunoblastic T
cell lymphoma; nNK/T, nasal type extranodal NK/T cell lym-
phoma; TBI, total body irridiation; CR1/PR1, first complete or
partial response.
Other: hepatosplenic (N 5 2), adult T cell leukemia/lymphoma
(N 5 1).
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purged in 86% of all cases. The median follow-up of
surviving patients was 4.9 years (range: 1.0-11.5).
Forty-four of 53 patients received CHOP (cyclo-
phosphamide, daunorubicin, vincristine, prednisone)
as initial induction therapy. Thirty-six patients re-
ceived additional regimens either during induction or
at relapse. Of these, 28 patients received a platinum
and cytarabine-based regimen, such as DHAP (dexa-
methasone, cytarabine, cisplatin) or ESHAP (etopo-
side, methylprednisolone, cytarabine, cisplatin), and
4 received a methotrexate-based regimen. No patients
received targeted therapy, novel agents, purine ana-
logues, or gemcitabine prior to AHCT.
Clinical Outcomes
For all patients, the estimated OS and PFS at
5 years were 48% and 25%, respectively. The PFS at
5 years for patients in CR1/PR1, CR2/PR21, and
REF were 51%, 12%, and 0, respectively. Corre-
sponding figures for OS at 5 years were 76%, 40%,
and 30%, respectively. Disease status at time of
AHCT had a significant impact on both OS (P 5
.03) and PFS (P 5 .01) (Figure 1). The median PFS
has not been reached for CR1/PR1 patients and is
1.3 years and 0.3 years for CR2/PR21 and REF pa-
tients, respectively. The median OS has not been
reached for patients in CR1/PR1 and is 2.2 years and
0.8 years for the CR2/PR2 and REF patients, respec-
tively. Of the 34 patients who developed progressive
disease, the median time to progression was 0.4 years
(range: 0.1-4.0). Progressive disease was the major
cause of treatment failure yielding a relapse mortality
of 49% (n5 26). Interestingly, 7 patients who relapsed
after AHCT had achieved a subsequent CR at last fol-
low-up. Three of these patients underwent reduced in-
tensity allogeneic HCT, and 4 patients received
salvage therapy outside of Stanford (details not avail-
able). Nonrelapse mortality (NRM) was 4% (n 5 2),
and both patients expired from treatment-related acute
myelogenous leukemia (AML) at 4 and 48 months
post-HCT.
By univariate analysis, disease status at the time of
AHCT was a significant factor for both OS and PFS
(Figure 1). Apart from disease status, the number of
prior regimens also was a significant pre-HCT predic-
tor for PFS and showed a trend toward significance for
OS (Figure 2). In contrast, survival outcomes were not
affected by type of PTCL, disease stage, bone marrow
involvement, B symptoms, sex, age, and duration of
first response for patients transplanted in CR2/PR21
(Table 2). After AHCT, CR status at day 190 post-
HCT was predictive for PFS and OS by both univari-
ate and multivariate analysis. Nine of 14 patients with
relapsed disease in partial response (PR2 or PR3) and 2
of 10 patients with primary REF converted to CR atday 190 post-HCT assessment. Of these 11 patients
who converted to CR, only 3 patients remain in con-
tinuous remission at last follow-up.
DISCUSSION
Despite high initial response rates, patients with
PTCL typically fare poorly after conventional chemo-
therapy. With the goal of overcoming the dismal
outcome seen in this patient population, intensive reg-
imens such as AHCT are offered as consolidation of
first remission and at relapse. This report summarizes
our retrospective review of patients with PTCL who
underwent AHCT at Stanford University since 1988.
Among the 53 patients in this report, 15 patients un-
derwent AHCT while in CR1/PR1, whereas the other
38 patients were in second remission or beyond or had
Figure 1. OS (P 5 .03) and PFS (P\ .01) based on disease status at
time of transplant.
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CR1/PR1 had a durable PFS. In contrast, only a small
minority of patients transplanted with relapsed disease
had prolonged PFS, and no patients with primary REF
experienced a sustained benefit.
Unlike other published series of AHCT in PTCL,
the patients in our study received purged autografts to
reduce potential tumor cell contamination. Autografts
were manipulated using monoclonal antibody and
complement through 2001, and CD341 selection of
the graft was performed after 2001. Despite the infu-
sion of a T cell purged graft, we did not observe a sig-
nificant increase in infections, and none of our patients
died of infectious complications. However, the high
relapse rate seen in our study was comparable to other
series where purging was not done. Therefore, tumor
Figure 2.OS (P5 .09) and PFS (P5 .01) based on number of prior
regimens.cell depletion via ex vivo T cell purging cannot be rou-
tinely recommended in this patient population.
We did not find a survival difference by type of
PTCL, although there were not sufficient numbers
to stratify by type and disease status. The City of
Hope series also did not find a survival difference based
on histology [11]. Some retrospective series have
reported improved survival in ALCL, but this likely re-
flected inclusion of relatively more cases of ALK1
ALCL [12,13]. In our series, 4 of 13 patients with
ALCL in CR2/PR21 are in continuous remission; 2
had ALK negative disease, and the ALK status of the
other 2 cases is unknown. Early disease progression
was common, and the median time to progression
was only 0.4 years in patients who progressed after
AHCT. Hence, patients who obtained or remained
in CR by day 190 had more favorable outcomes.
The patients who appeared to benefit from AHCT
were those in first remission at the time of AHCT. The
15 patients who underwent AHCT in CR1/PR1 had
a 5-year PFS and OS of 51% and 87%, respectively,
with a plateau in the survival curve at a median fol-
low-up of 59 months. Table 3 lists the characteristics
of this favorable subset of patients. Investigators from
the City of Hope also demonstrated a superior DFS
and OS in the 12 patients who were in CR1 at AHCT
compared to patients who were not in CR1 (DFS:
83% versus 35%; P 5 .03 and OS: 83% versus 45%,
P 5 .006, respectively) in their retrospective series of
57 patients with a median follow-up of 22 months
[11]. A large SouthKoreanmulticenter retrospective se-
ries of 139 patients also reported improved survival in
patients who underwent AHCT in CR1/PR1 (n 5 58)
compared to those with relapsed or REF with a
median follow-up of 29 months [14]. The Spanish
GEL-TAMO (Spanish Group for Lymphoma and Au-
tologous Transplantation) group published a large ret-
rospective series of 75 patients who underwent AHCT
as consolidation in first remission for PTCL with
Table 2. Univariate Analysis of Prognostic Factors
Variable OS PFS
Disease status
at AHCT
.03 \.01
Number prior regimens .09 .01
Histology subtype .87 .72
Sex .21 .95
Age .50 .87 .15
Stage III or IV .87 .15
B symptoms .85 .87
Bone marrow involvement .90 .29
CR1 .1 year * .77 .98
CR at day 190 post AHCT \.01 \.01
AHCT indicates autologous hematopoietic cell transplant; OS,
overall survival; PFS, progression-free survival; CR, complete re-
mission.
*Restricted to patients with relapsed disease.
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Age Stage Histology Prior Regimens (#)
Status at
AHCT Outcome
*Duration
(months)
51 IV AITL CHOP, hyperCVAD (2) PR1 REL 15
53 IV AITL CHOP (1) CR1 REL 7
53 IV AITL CHOP, ESHAP (2) CR1 REL 8
63 IV AITL CHOP (1) CR1 CR 12
45 IV ALCL, Alk1 CHOP, ESHAP, Bleomycin/paclitaxel (3) PR1 CR 86
51 III ALCL, Alk- CHOP, hyper CVAD (2) PR1 EXP 1
38 IV Hepatosplenic CHOP (1) CR1 CR 61
43 IV Hepatosplenic CHOP (1) CR1 CR 81
18 IV nNK/T Multiagent (1) CR1 EXP 1
40 I nNK/T CHOP 1 MTX 1 XRT (1) CR1 CR 60
43 IV nNK/T CHOP, hyperCVAD (2) CR1 CR 22
47 I nNK/T CHOP (1) CR1 EXP 23
49 I nNK/T CHOP, DHAP 1 XRT (2) PR1 CR 72
54 III PTCL-U CHOP (1) CR1 REL 5
54 IV PTCL-U CHOP (1) CR1 CR 162
PR indicates partial response; CR, complete response; REL, relapse; EXP, expired (all deaths [EXP] were because of relapse; CHOP, cyclophos-
phamide, doxorubicin, vincristine, prednisone; Hyper CVAD, fractionated cyclophosphamide, doxorubicin, vincristine, prednisone,
methotrexate, cytarabine; DHAP, dexamethasone, cytarabine, cisplatin; ESHAP, etoposide, methylprednisolone, cytarabine, cisplatin;
Multi-Agent: see [27]; XRT, external radiation. See Table 1 for other abbreviations.
Notes: *Duration refers to time to progression for relapsed/expired patients and length of follow-up for patients in continuous CR.a median follow-up of 67 months from diagnosis [13].
The 5-year PFS and OS were an encouraging 63%
and 68%, respectively, for all patients. However, the
outcome of patients with ALCL was significantly supe-
rior compared to other histologies, and ALK status was
not available in most cases. Hence, inclusion of patients
withALK1ALCL likely biased the results in this series.
Thus, given the poor outcomes with conventional
chemotherapy and the encouraging retrospective re-
sults, the role of AHCT as consolidation therapy in
first remission has been explored prospectively. A Ger-
man study incorporated AHCT as frontline consolida-
tion for PTCL-U and AITL after 4-6 cycles of CHOP
and reported a PFS of 76% among the 21 patients who
actually proceeded to AHCT [15]. However, median
follow-up was only 15 months. The Spanish GEL-
TAMO group also conducted a prospective trial of
AHCT as frontline consolidation for PTCL, exclud-
ing ALK1 ALCL, and reported an encouraging OS
and PFS of 84% and 56% at 2 years following
AHCT in 19 patients [6]. In contrast, an Italian report
combined the results of 2 prospective phase 2 trials
utilizing high dose sequential therapy or MACOP-B
followed by AHCT in advanced stage PTCL and
reported disappointing results [5]. The 12-year esti-
mated DFS and OS were 30% and 34%, respectively,
at a median follow-up of 76 months. Excluding ALK1
ALCL, the estimated 12 year EFS was only 18%. This
was an intent-to-treat analysis, and 16 patients (26%)
who did not undergo AHCT were included in the sur-
vival data. In the above-mentioned German and Span-
ish studies, nearly 1/3 of patients did not proceed to
AHCT because of inadequate responses to induction
chemotherapy and were not included in the survivalanalysis, likely explaining the discrepancy with the Ital-
ian results.
The survival outcomes for our patients with re-
lapsed or REF were lower than other reported series
(Table 4) [2,4,11,12,14,16-18]. Duration of follow-
up was relatively short in most published reports,
and only the Spanish GEL-TAMO and Memorial
Sloan Kettering retrospective reports have long
follow-up comparable to our series. Of note, 36% of
patients in the GEL-TAMO series were in PR1, al-
though they were classified in analysis as relapsed/
REF status, and 1/3 of patients in the Memorial Sloan
Table 4. Autologous Hematopoietic Cell Transplantation for Relapsed and
Refractory PTCL
Group N DFS/PFS OS
Median
Follow-up
(years)
Stanford: Relapsed 28 12% 40% 4.9
Stanford: Refractory 10 0 30% 4.9
South Korea: Relapsed [14] 73 33% 33% 2.4
South Korea: Refractory [14] 12 0 0 2.4
GEL-TAMO [4]* 123 34% 45% 5.1
BSBMT/ABMTRR [17] 64 50% 53% 3.1
Memorial Sloan Kettering [2] 24 24% 33% 6
City of Hope [11] 45 45% 35% 1.8
Vanderbilt [12] 28 50% 69% 3
Princess Margaret Hospital [18] 36 37% 48% 3.5
Sweden [16] 40 48% 58% 2.1
DFS/PFS indicates disease/progression free survival; OS, overall
survival; GEL-TAMO, Spanish Group for Lymphoma and Au-
tologous Transplantation; BSBMT/ABMTRR, British Society
for Blood and Marrow Transplantation/Australasian Bone Mar-
row Transplant Recipient Registry.
Notes: *Included patients in first partial remission.
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based on response to first line therapy but were actu-
ally in PR1 prior to AHCT after a second induction
regimen [2,4]. In our series, those patients would
have been classified as CR1/PR1, and many of our
CR1/PR1 patients required multiple induction regi-
mens. Hence, the worse survival in our series is likely
because of more stringent classification of relapsed
and REF and perhaps better reflects the true poor out-
come of such patients with conventional salvage che-
motherapy and AHCT.
Although chemosensitivity prior to AHCT has
been identified as prognostic for survival [2,19], all of
the relapsed patients in our series were chemosensitive
to salvage therapy but still had poor outcomes. Over
80% of our patients received CHOP first line, and
nearly 90% received a platinum, cytarabine, or metho-
trexate-based regimen as salvage. Novel therapies,
such as monoclonal antibodies, histone deacetylase in-
hibitors, and new antimetabolites, have shown promise
in nontransplant trials [20-23]. Because conventional
lymphoma regimens are not adequate for PTCL, in-
clusion of novel therapies into pretransplant salvage
and conditioning regimens should be explored, partic-
ularly for relapsed and REF. Prognostic scoring
systems, such as the IPI and modified PIT [24,25],
can identify high-risk patients at diagnosis who might
benefit from novel therapies in combination with
front-line consolidation AHCT.
Because of the limitations of AHCT, allogeneic
HCT has also been explored in PTCL. Myeloablative
allogeneic HCT has been associated with high NRM,
but reduced-intensity conditioning (RIC) has shown
promising results [17,26]. We have offered a reduced-
intensity allogeneic HCT to 5 patients with relapsed
PTCL after prior AHCT, and 3 patients remain in re-
mission at a median follow-up of 27 months. We are
also exploring tandem AHCT followed by reduced in-
tensity allogeneicHCT for patients with relapsed/REF.
In conclusion, our results demonstrate that pa-
tients with relapsed or REF derive minimal long-
term benefit from conventional salvage therapy and
AHCT. Hence, novel agents and allogeneic HCT
deserve further study and should be incorporated early
in the treatment course of this challenging patient
population. Our findings support the use of AHCT
as consolidation therapy in PTCL, but prospective
randomized trials are needed to confirm benefit in pa-
tients responding to front-line therapy. Given the rar-
ity and diversity of PTCL, the relative roles of AHCT,
allogeneic HCT, and novel agents will likely require
collaborative efforts for further progress.
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